Trade names Posicor Routes of
administration By mouth (tablets) Legal status Withdrawn from market Bioavailability 70% | MedlinePlus a607007 ATC code C08CX01 (WHO) Molar mass 495.63 g/mol | |
 | ||
AHFS/Drugs.com Micromedex Detailed Consumer Information | ||
Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.
The mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels, which is probably responsible for many of its unique properties.
It is nonselective.
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications.
References
Mibefradil Wikipedia(Text) CC BY-SA